CDC advisors meet on Friday to determine the fate of Johnson & Johnson’s COVID-19 vaccine – NBC4 Washington

The Government Advisory Committee on Vaccines will meet on Friday to make immediate recommendations on whether and how to resume the use of Johnson & Johnson vaccines.

The Immunization Advisory Board will meet Friday from 11:00 am to 5:00 pm to vote on the latest recommendations for the use of vaccines that have been suspended in the United States for more than a week due to concerns about blood clots. ..

The Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement on April 13 to ask federal and state agencies to suspend the deployment of the J & J vaccine after a few abnormal blood clots were associated with the shot. I’m looking for it.

At that time, authorities were examining six reports of abnormal blood clots, including death, among more than 7 million Americans who received a single vaccination. Two more cases were reported this week in Oregon and Texas.

Oregon health officials said Thursday they were investigating the deaths of a woman in her 50s who developed rare blood clots and low platelets within two weeks of Johnson & Johnson vaccination. The unnamed woman was given before the CDC ordered the vaccine to be suspended, fearing it could cause dangerous blood clots.

Also on Thursday, federal health officials told the Texas Department of Health that a rare blood coagulation disorder that occurred after a Texas woman received a J & J shot was “a symptom that seems to be consistent with some other reported cases.” I have notified that I have been hospitalized. An official spokesman said no other information was disclosed, citing patient privacy and confidentiality.

It is not yet known why some patients who have been vaccinated with the J & J vaccine have rare blood clots. The six people who experienced blood clots were all women between the ages of 18 and 48, and symptoms appeared 6 to 13 days after receiving the injection, the FDA and CDC said. They had so-called cerebral sinus thrombosis, or CVST, and low levels of platelets. Two newly reported cases are also among women.

The FDA and CDC, which have suspended the use of the J & Janssen vaccine, signal doctors across the country to look for rare blood clots in six of the millions of patients vaccinated with this brand. And how to treat these blood clots, Dr. John Torres, senior medical correspondent at NBC News, explains.

So far, concerns about abnormal blood clots have focused on vaccines from AstraZeneca, which has not yet been approved in the United States. Earlier this month, European regulators said they had discovered a possible link between shots and the very rare type of blood clots that occur. It seems to occur more often in young people, along with low platelets.

J & J and AstraZeneca vaccines are made with the same technology. Unlike the Pfizer and Moderna vaccines, which train the body to recognize the peplomer that covers the outer surface of the coronavirus, the J & J and AstraZeneca vaccines use a cold virus called adenovirus to put the peagen into the body. I will carry it. J & J uses human adenovirus to create the vaccine, and AstraZeneca uses the chimpanzee version.

This week, the European Medicines Agency (European Union drug regulator) decided that warnings about abnormal blood clots associated with low levels of platelets should be added to product information, but the benefits of the vaccine outweigh the risks. I concluded.

The most widely used COVID-19 vaccine in the United States (Pfizer and Modana two-shot vaccine) and the FDA say there are no signs of similar clot concerns with these vaccines.

CDC advisors meet on Friday to determine the fate of Johnson & Johnson’s COVID-19 vaccine – NBC4 Washington

Source link CDC advisors meet on Friday to determine the fate of Johnson & Johnson’s COVID-19 vaccine – NBC4 Washington

Related Articles

Back to top button